Crossmark

Is GRK2 a new target for cardiovascular disease?

Crossref DOI link: https://doi.org/10.1038/s41440-018-0052-2

Published Online: 2018-05-23

Published Print: 2018-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Oyama, Jun-ichi

Node, Koichi
License Information

Text and Data Mining valid from 2018-05-23
More Information

Article History

Received: 25 March 2018

Accepted: 10 April 2018

First Online: 23 May 2018

Compliance with ethical standards

:

: JO belongs to the endowed Department of Fukuda Denshi Co, Ltd. KN received remuneration including lecture fees from AstraZeneca, Astellas Pharma Inc., Nippon Boehringer Ingelheim Co, Ltd., Pfizer Inc., MSD KK, Daiichi Sankyo Company, Ltd., Kowa Pharmaceutical Co, Ltd., Takeda Pharmaceutical Co, Ltd., Novartis Pharmaceuticals Japan, Mitsubishi Tanabe Pharma Corporation, and Dainippon Sumitomo Pharma Co, Ltd. KN also received scholarship funds or donations granted by Astellas Pharma Inc., Nippon Boehringer Ingelheim Co, Ltd., Daiichi Sankyo Company, Ltd., Takeda Pharmaceutical Co, Ltd., Mitsubishi Tanabe Pharma Corporation, and MSD KK.